Literature DB >> 12006368

Effects of recurrent hyperinsulinemia with and without hypoglycemia on counterregulation in diabetic rats.

Karen Inouye1, Kathy Shum, Owen Chan, Julian Mathoo, Stephen G Matthews, Mladen Vranic.   

Abstract

To understand the mechanisms whereby recurrent hypoglycemia increases the risk of subsequent hypoglycemia, it was necessary to differentiate the effects of recurrent hyperinsulinemia from those of hyperinsulinemic hypoglycemia. We examined basal and hypoglycemic endocrine function in normal rats, streptozotocin-diabetic controls, and diabetic rats exposed to 4 days of 2 episodes/day of hyperinsulinemic hypoglycemia (DH) or hyperinsulinemic hyperglycemia (DI). DH and DI rats differentiated the effects of hyperinsulinemia from those of hypoglycemia. In diabetic controls, basal plasma ACTH tended to be increased, and plasma corticosterone, plasma somatostatin, and pancreatic prosomatostatin and proglucagon mRNA were increased (P < 0.05) vs. normal rats. These parameters were normalized in DH and DI rats. In diabetic controls, glucagon, epinephrine, norepinephrine, corticosterone, and peak glucose production responses to hypoglycemia were reduced (P < 0.05) vs. normal rats. In DI rats, epinephrine responses were normalized. Conversely, DH rats displayed marked further impairment of epinephrine and glucose production responses and increased peripheral insulin sensitivity (P < 0.05 vs. diabetic controls). Both insulin regimens partially normalized glucagon and fully normalized norepinephrine and corticosterone responses. In summary, recurrent hyperinsulinemia in diabetic rats normalized most pituitary-adrenal, sympathoadrenal, and pancreatic parameters. However, concurrent hypoglycemia further impaired epinephrine and glucose production responses and increased insulin sensitivity. We conclude that 1) recurrent hypoglycemia may increase the risk of subsequent hypoglycemia by increasing insulin sensitivity, and 2) epinephrine counterregulation is particularly sensitive to impairment by recurrent hypoglycemia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12006368     DOI: 10.1152/ajpendo.00480.2001

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  11 in total

1.  Hypoglycemia risk and glucose variability indices derived from routine self-monitoring of blood glucose are related to laboratory measures of insulin sensitivity and epinephrine counterregulation.

Authors:  Achilleas N Pitsillides; Stacey M Anderson; Boris Kovatchev
Journal:  Diabetes Technol Ther       Date:  2011-01       Impact factor: 6.118

Review 2.  From bedside to bench and back again: research issues in animal models of human disease.

Authors:  Nancy C Tkacs; Hilaire J Thompson
Journal:  Biol Res Nurs       Date:  2006-07       Impact factor: 2.522

3.  A model of self-treatment behavior, glucose variability, and hypoglycemia-associated autonomic failure in type 1 diabetes.

Authors:  Marc Breton; William L Clarke; Leon Farhy; Boris Kovatchev
Journal:  J Diabetes Sci Technol       Date:  2007-05

4.  Brain insulin action regulates hypothalamic glucose sensing and the counterregulatory response to hypoglycemia.

Authors:  Kelly A Diggs-Andrews; Xuezhao Zhang; Zhentao Song; Dorit Daphna-Iken; Vanessa H Routh; Simon J Fisher
Journal:  Diabetes       Date:  2010-06-14       Impact factor: 9.461

Review 5.  Mini-review: impact of recurrent hypoglycemia on cognitive and brain function.

Authors:  Ewan C McNay; Victoria E Cotero
Journal:  Physiol Behav       Date:  2010-01-22

6.  Insulin-like stimulation of cardiac fuel metabolism by physiological levels of glucagon: involvement of PI3K but not cAMP.

Authors:  Julie A Harney; Robert L Rodgers
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-05-20       Impact factor: 4.310

7.  Glucagon secretion and signaling in the development of diabetes.

Authors:  Herbert Y Gaisano; Patrick E Macdonald; Mladen Vranic
Journal:  Front Physiol       Date:  2012-09-04       Impact factor: 4.566

8.  Somatostatin receptor type 2 antagonism improves glucagon and corticosterone counterregulatory responses to hypoglycemia in streptozotocin-induced diabetic rats.

Authors:  Jessica T Y Yue; Elena Burdett; David H Coy; Adria Giacca; Suad Efendic; Mladen Vranic
Journal:  Diabetes       Date:  2011-11-21       Impact factor: 9.461

9.  Somatostatin Receptor Antagonism Reverses Glucagon Counterregulatory Failure in Recurrently Hypoglycemic Male Rats.

Authors:  Emily G Hoffman; Mahsa Jahangiriesmaili; Erin R Mandel; Caylee Greenberg; Julian Aiken; Ninoschka C D'Souza; Aoibhe Pasieka; Trevor Teich; Owen Chan; Richard Liggins; Michael C Riddell
Journal:  Endocrinology       Date:  2021-12-01       Impact factor: 5.051

10.  Posttranscriptional regulation of adrenal TH gene expression contributes to the maladaptive responses triggered by insulin-induced recurrent hypoglycemia.

Authors:  Necla Kudrick; Owen Chan; Edmund F La Gamma; Juhye Lena Kim; Arnold William Tank; Carol Sterling; Bistra B Nankova
Journal:  Physiol Rep       Date:  2015-02-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.